MX2020004112A - Provision de un regimen de dosificacion de farmaco farmacocinetico. - Google Patents
Provision de un regimen de dosificacion de farmaco farmacocinetico.Info
- Publication number
- MX2020004112A MX2020004112A MX2020004112A MX2020004112A MX2020004112A MX 2020004112 A MX2020004112 A MX 2020004112A MX 2020004112 A MX2020004112 A MX 2020004112A MX 2020004112 A MX2020004112 A MX 2020004112A MX 2020004112 A MX2020004112 A MX 2020004112A
- Authority
- MX
- Mexico
- Prior art keywords
- dosage regimen
- regimen
- plasma protein
- dosing regimen
- therapeutic plasma
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/50—Mutagenesis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/20—Supervised data analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/30—Unsupervised data analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
- G16B5/20—Probabilistic models
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/30—Prediction of properties of chemical compounds, compositions or mixtures
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C99/00—Subject matter not provided for in other groups of this subclass
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Computational Biology (AREA)
- Theoretical Computer Science (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Evolutionary Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Data Mining & Analysis (AREA)
- Primary Health Care (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Computing Systems (AREA)
- Databases & Information Systems (AREA)
- Physiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Bioethics (AREA)
- Software Systems (AREA)
- Evolutionary Computation (AREA)
- Artificial Intelligence (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Probability & Statistics with Applications (AREA)
Abstract
Se describen un sistema y método para proporcionar un régimen de dosificación de proteína plasmática terapéutica que incluye determinar un perfil farmacocinetico de un paciente utilizando un modelo Bayesiano de perfiles farmacocinéticos de pacientes muestreados. El sistema y método ilustrativos también incluyen determinar un primer régimen de dosificación durante un primer intervalo de dosificación especificado que incluye (i) una primera dosis y (ii) un primer nivel de proteína plasmática terapéutica en el paciente durante un periodo de tiempo basado al menos en el perfil farmacocinético, y determinar un segundo régimen de dosificación durante un segundo intervalo de dosificación especificado que incluye (i) una segunda dosis y (ii) un segundo nivel de proteína plasmática terapéutica en el paciente durante el periodo de tiempo basándose en al menos el perfil farmacocinético. El sistema y método ilustrativos además incluyen presentar el primer régimen de dosificación y el segundo régimen de dosificación en un dispositivo de cliente de manera que el primer régimen de dosificación se presenta junto con el segundo régimen de dosificación.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361837421P | 2013-06-20 | 2013-06-20 | |
| US201361840969P | 2013-06-28 | 2013-06-28 | |
| US201361881214P | 2013-09-23 | 2013-09-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020004112A true MX2020004112A (es) | 2020-07-24 |
Family
ID=52111779
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015017878A MX373454B (es) | 2013-06-20 | 2014-06-20 | Provision de un regimen de dosificacion de farmaco farmacocinetico. |
| MX2023000359A MX2023000359A (es) | 2013-06-20 | 2015-12-18 | Provision de un regimen de dosificacion de farmaco farmacocinetico. |
| MX2020004112A MX2020004112A (es) | 2013-06-20 | 2015-12-18 | Provision de un regimen de dosificacion de farmaco farmacocinetico. |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015017878A MX373454B (es) | 2013-06-20 | 2014-06-20 | Provision de un regimen de dosificacion de farmaco farmacocinetico. |
| MX2023000359A MX2023000359A (es) | 2013-06-20 | 2015-12-18 | Provision de un regimen de dosificacion de farmaco farmacocinetico. |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20140379629A1 (es) |
| EP (3) | EP3879534A1 (es) |
| JP (4) | JP2016526542A (es) |
| KR (4) | KR102296042B1 (es) |
| CN (2) | CN105592973B (es) |
| AU (3) | AU2014287706B2 (es) |
| BR (3) | BR122020013811A8 (es) |
| CA (1) | CA2915472C (es) |
| CL (1) | CL2015003641A1 (es) |
| EA (1) | EA037962B1 (es) |
| ES (1) | ES2882832T3 (es) |
| GE (4) | GEP20196990B (es) |
| IL (3) | IL279313B (es) |
| MX (3) | MX373454B (es) |
| MY (2) | MY195911A (es) |
| NZ (1) | NZ715216A (es) |
| PH (1) | PH12015502800B1 (es) |
| PL (1) | PL3010681T3 (es) |
| SA (2) | SA515370289B1 (es) |
| SG (1) | SG11201510515YA (es) |
| UA (1) | UA118109C2 (es) |
| WO (1) | WO2015006033A1 (es) |
| ZA (1) | ZA201600100B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014014106A2 (pt) * | 2011-12-13 | 2017-06-13 | Koninklijke Philips Nv | sistema, e método |
| WO2014055978A1 (en) | 2012-10-05 | 2014-04-10 | Baysient LLC | System and method for providing patient-specific dosing as a function of mathematical models |
| US10325687B2 (en) * | 2013-12-06 | 2019-06-18 | Bioverativ Therapeutics Inc. | Population pharmacokinetics tools and uses thereof |
| WO2015154090A1 (en) | 2014-04-04 | 2015-10-08 | Bloodworks | Routine laboratory and point-of-care (poc) testing for hemostasis |
| US11062797B2 (en) * | 2014-10-10 | 2021-07-13 | Continuous Precision Medicine | Method and system for obtaining and using pharmacokinetic data in drug administration |
| US11501863B2 (en) * | 2015-04-09 | 2022-11-15 | Diane R. MOULD | Systems and methods for patient-specific dosing |
| WO2017136583A1 (en) * | 2016-02-02 | 2017-08-10 | Versartis, Inc. | Growth hormone treatment adherence system |
| CN109804432B (zh) * | 2016-04-15 | 2023-07-14 | 武田药品工业株式会社 | 提供药代动力学药物给药方案的方法和设备 |
| JP6807015B2 (ja) * | 2016-06-13 | 2021-01-06 | ソニー株式会社 | 情報処理装置、情報処理方法、およびプログラム |
| US10896749B2 (en) * | 2017-01-27 | 2021-01-19 | Shire Human Genetic Therapies, Inc. | Drug monitoring tool |
| WO2018144373A1 (en) * | 2017-02-01 | 2018-08-09 | Shire Human Genetic Therapies, Inc. | A physiological sensing and therapeutic administration system and method |
| US12347538B2 (en) * | 2019-02-06 | 2025-07-01 | OptimDosing, LLC | Smart multidosing |
| BE1027052A1 (fr) | 2019-02-14 | 2020-09-07 | Aardex Group | Procede d'assistance a la prise ou a l'acte d'un traitement therapeutique |
| US10970651B1 (en) * | 2019-12-02 | 2021-04-06 | Sas Institute Inc. | Analytic system for two-stage interactive graphical model selection |
| KR102420872B1 (ko) * | 2020-12-18 | 2022-07-14 | 포항공과대학교 산학협력단 | 강화학습과 약동-약력학 모델을 이용한 연속 약물 투여량 결정 방법 |
| CN113053508B (zh) * | 2021-03-29 | 2024-07-26 | 深圳市科曼医疗设备有限公司 | 基于触控屏的交互控制方法及装置 |
| US12444172B2 (en) * | 2022-11-28 | 2025-10-14 | GE Precision Healthcare LLC | Variable confidence machine learning |
| CN116844662B (zh) * | 2023-06-29 | 2026-03-27 | 中国科学技术大学 | 一种药剂投加方案的选取方法、装置和计算机可读介质 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07124125A (ja) * | 1993-11-04 | 1995-05-16 | S R L:Kk | 薬物投与解析システム |
| SI0796623T1 (en) * | 1996-03-20 | 2005-10-31 | Baxter Aktiengesellschaft | Pharmaceutical preparation for the treatment of blood coagulation disorders |
| AU5219798A (en) * | 1996-12-09 | 1998-07-03 | Samuel David | Gpi-ceruloplasmin, analogs thereof, and methods of use |
| WO2000067776A1 (en) * | 1999-05-11 | 2000-11-16 | Ortho-Mcneil Pharmaceuticals, Inc. | Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration |
| US7860583B2 (en) * | 2004-08-25 | 2010-12-28 | Carefusion 303, Inc. | System and method for dynamically adjusting patient therapy |
| US20040023211A1 (en) * | 2000-09-15 | 2004-02-05 | Kees Groen | System and method for optimizing drug theraphy for the treatment of diseases |
| CA2514571C (en) * | 2003-02-01 | 2019-01-15 | Baxter International Inc. | Wireless medical data communication system and method |
| EP1642607A1 (en) * | 2004-10-04 | 2006-04-05 | Sanofi-Aventis Deutschland GmbH | Dose display mechanism for a drug delivery device |
| JP2006155071A (ja) * | 2004-11-26 | 2006-06-15 | Toshiba Sumiden Medical Information Systems Corp | 電子カルテ薬物療法指示実施システム |
| US20060183786A1 (en) * | 2005-02-16 | 2006-08-17 | Chi Mei Foundation Hospital | Injectable long-acting analgesic composition comprising an ester derivative of ketorolac |
| US8589175B2 (en) | 2005-11-29 | 2013-11-19 | Children's Hospital Medical Center | Optimization and individualization of medication selection and dosing |
| WO2009120991A2 (en) * | 2008-03-27 | 2009-10-01 | Medtronic, Inc. | Pharmacokinetic and pharmacodynamic tools to define patient specific therapeutic regimens |
| US8591454B2 (en) * | 2008-11-10 | 2013-11-26 | The Invention Science Fund I, Llc | Administering a therapeutic agent with more than one taggant |
| EP4382170A3 (en) * | 2009-12-06 | 2024-09-04 | Bioverativ Therapeutics Inc. | Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof |
-
2014
- 2014-06-20 EA EA201690048A patent/EA037962B1/ru unknown
- 2014-06-20 UA UAA201600443A patent/UA118109C2/uk unknown
- 2014-06-20 GE GEAP201414559A patent/GEP20196990B/en unknown
- 2014-06-20 MX MX2015017878A patent/MX373454B/es active IP Right Grant
- 2014-06-20 EP EP21170633.8A patent/EP3879534A1/en active Pending
- 2014-06-20 EP EP14823224.2A patent/EP3010681B1/en active Active
- 2014-06-20 CN CN201480046279.5A patent/CN105592973B/zh active Active
- 2014-06-20 KR KR1020167001142A patent/KR102296042B1/ko active Active
- 2014-06-20 NZ NZ715216A patent/NZ715216A/en unknown
- 2014-06-20 KR KR1020217026984A patent/KR102352133B1/ko active Active
- 2014-06-20 SG SG11201510515YA patent/SG11201510515YA/en unknown
- 2014-06-20 AU AU2014287706A patent/AU2014287706B2/en active Active
- 2014-06-20 PL PL14823224T patent/PL3010681T3/pl unknown
- 2014-06-20 GE GEAP201814039A patent/GEAP201814039A/en unknown
- 2014-06-20 BR BR122020013811A patent/BR122020013811A8/pt not_active Application Discontinuation
- 2014-06-20 MY MYPI2020003916A patent/MY195911A/en unknown
- 2014-06-20 GE GEAP201414039A patent/GEP20186882B/en unknown
- 2014-06-20 GE GEAP201914559A patent/GEAP201914559A/en unknown
- 2014-06-20 ES ES14823224T patent/ES2882832T3/es active Active
- 2014-06-20 MY MYPI2015704622A patent/MY176173A/en unknown
- 2014-06-20 KR KR1020227001162A patent/KR102397974B1/ko active Active
- 2014-06-20 US US14/311,113 patent/US20140379629A1/en not_active Abandoned
- 2014-06-20 BR BR122022000127A patent/BR122022000127A8/pt not_active Application Discontinuation
- 2014-06-20 WO PCT/US2014/043517 patent/WO2015006033A1/en not_active Ceased
- 2014-06-20 JP JP2016521871A patent/JP2016526542A/ja active Pending
- 2014-06-20 IL IL279313A patent/IL279313B/en unknown
- 2014-06-20 BR BR112015031856A patent/BR112015031856A8/pt not_active Application Discontinuation
- 2014-06-20 KR KR1020227015723A patent/KR20220065097A/ko not_active Ceased
- 2014-06-20 CN CN202010499366.3A patent/CN111508557B/zh active Active
- 2014-06-20 EP EP17197995.8A patent/EP3309696A1/en not_active Withdrawn
- 2014-06-20 CA CA2915472A patent/CA2915472C/en active Active
-
2015
- 2015-12-16 CL CL2015003641A patent/CL2015003641A1/es unknown
- 2015-12-16 PH PH12015502800A patent/PH12015502800B1/en unknown
- 2015-12-17 IL IL243208A patent/IL243208B/en active IP Right Grant
- 2015-12-17 SA SA515370289A patent/SA515370289B1/ar unknown
- 2015-12-17 SA SA521430246A patent/SA521430246B1/ar unknown
- 2015-12-18 MX MX2023000359A patent/MX2023000359A/es unknown
- 2015-12-18 MX MX2020004112A patent/MX2020004112A/es unknown
-
2016
- 2016-01-06 ZA ZA2016/00100A patent/ZA201600100B/en unknown
-
2017
- 2017-12-07 AU AU2017272293A patent/AU2017272293B2/en active Active
-
2019
- 2019-05-22 JP JP2019095949A patent/JP6813237B2/ja active Active
-
2020
- 2020-04-21 AU AU2020202664A patent/AU2020202664B2/en active Active
- 2020-05-21 IL IL274848A patent/IL274848A/en active IP Right Grant
- 2020-12-11 JP JP2020205945A patent/JP7060291B2/ja active Active
-
2022
- 2022-04-11 JP JP2022065039A patent/JP7398031B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015017878A (es) | Provision de un regimen de dosificacion de farmaco farmacocinetico. | |
| MX2022012914A (es) | Dispositivos y metodos para administracion y mezcla de farmaco, y entrenamiento de tecnicas apropiadas para ello. | |
| SG10201804607RA (en) | System and method for facilitating delivery of patient-care | |
| ZA201807214B (en) | Method and apparatus for providing a pharmacokinetic drug dosing regiment | |
| IN2015DN03826A (es) | ||
| MX2025007908A (es) | Aparatos, metodos y sistemas para administrar medicamento utilizando kits de medicamento | |
| MX2017008000A (es) | Sistema de inyeccion de un solo uso. | |
| CL2016000641A1 (es) | Un controlador para un dispositivo para administrar un medio de contraste que comprende un agente de contraste radiológico en un paciente usando un inyector, y método para determinar el volumen óptimo de un medio de contraste que comprende un agente de contraste radiológico que ha de administrarse en un paciente, antes de la administración. | |
| MX2016000103A (es) | Dispositivo de administracion de farmaco oral y metodos de uso del mismo. | |
| AR109946A1 (es) | Páncreas artificial | |
| BR112017022984A2 (pt) | dispositivo para facilitar o posicionamento de um cateter para administrar um medicamento em um paciente que esteja respirando espontaneamente | |
| EA202190596A3 (ru) | Предоставление фармакокинетической схемы дозирования лекарственного средства | |
| Montoro De Francisco | Local pustulosis: case report | |
| Yavelov | Practical Aspects of the Use of Oral Anticoagulant Rivaroxaban for the Prevention of Adverse Outcomes After Acute Coronary Syndrome | |
| Lai | Pityriasis rosea-like eruption, fever and liver dysfunction: case report | |
| MA38685A1 (fr) | Fourniture d'un régime de dosage de médicament pharmacocinétique | |
| Zhao et al. | Long-term follow-up in patients with Brugada Syndrome: a Southern Chinese experience |